Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyxeos in Relapsed/Refractory ALL
NCT03575325Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cytarabine in acute lymphoblastic leukemia (ALL), sponsored by Moffitt Cancer Center. Started Oct 2018; status: completed.
02
Drugs
cytarabine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03575325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03575325.